Real-World Overall Survival (Os) And Time To Therapy Discontinuation (Ttd) Of Patients (Pts) With Mcrpc Treated With Second-Generation Novel Hormonal Therapies (Nht) Associated With Tissue-Based Comprehensive Genomic Profiling (Cgp).

Ryon Graf,Russell Madison,Ole Gjoerup,Lei Zhong,Samantha Morley, Sunandini Chopra,Leah Comment,Virginia Fisher,Gerald Li,Kimberly McGregor,Alexa Betzig Schrock,Hanna Tukachinsky, Tamara Snow, Cheryl D. Cho-Phan, Akshay Swaminathan,Jeffrey S. Ross,Margaret Elizabeth McCusker,Amado J. Zurita,Jeffrey Venstrom

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览4

暂无评分

摘要

142Background: Robust biomarkers for personalization of NHT treatment decisions remains an unmet need. Most assessments of candidate biomarkers to predict NHT resistance have been conducted in clin...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要